ArticleAlpha psychiatry2025
High Mobility Group Box 1 Protein as a Biomarker in Adult Attention Deficit Hyperactivity Disorder.
Article in Alpha psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: Attention deficit hyperactivity disorder (ADHD), while representing the most frequently diagnosed and treated condition in child and adolescent psychiatry, continues to be underrecognized and inadequately managed in adult populations. Numerous studies have explored how ADHD may be connected to the immune system and inflammatory processes. These studies have focused particularly on ADHD, stress, anxiety and immune dysregulation. High Mobility Group Box 1 (HMGB1), a nuclear transcription factor and a late-phase mediator of inflammation, has been found to be elevated in various neuropsychiatric conditions. This study aimed to elucidate the potential contribution of inflammatory mechanisms to the pathophysiology of ADHD by quantifying HMGB1 levels. Materials and Methods: 43 ADHD patients and 42 controls with an age between 18-65 years were enrolled. Patients with any acute or chronic psychiatric disease, chronic inflammatory or autoimmune disease, substance addiction, malignancy, severe systemic disease, schizophrenia, mental retardation, a history of surgery or head trauma in the last 6 months and who were on vitamin or fish oil supplements or steroids were excluded. Blood samples were obtained and HMGB1 was measured with Enzyme-Linked Immuno Sorbent Assay method. Results: The two groups exhibited comparable sociodemographic characteristics. HMGB1 levels were significantly higher in ADHD group than controls (967.5 ± 462.0 ng/mL vs 693.4 ± 366.9 ng/mL, Conclusion: In our study, the finding that HMGB1 serum levels were higher in adult ADHD patients compared to healthy controls supports the hypothesis that chronic low-grade inflammation, which is both driven and detected by HMGB1, may be associated with ADHD through the possibility of causing neurodevelopmental disorders. It is known that HMGB1 is effective in the diagnosis and prognosis of immune system diseases. Therefore, our results show that HMGB1 may be related to the pathophysiology of ADHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.